Target intelligence / Profile preview

cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A)

Target: PDE10A
Molecular classification: Enzyme, Phosphodiesterase

Overview

cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A) is an enzyme that hydrolyzes both cAMP and cGMP, regulating intracellular signaling. It is highly expressed in the basal ganglia/striatum and is a therapeutic target for neurological disorders, particularly schizophrenia. Inhibitors of PDE10A are being developed and tested as potential treatments.

Mechanism of action

Inhibition of PDE10A increases cAMP and cGMP levels in the striatum, potentially improving neuronal signaling and function.

Biological functions

Signal transductionRegulation of intracellular cAMP and cGMP levels

Disease associations

SchizophreniaObesity

Interacting drugs

AMG-579

7 more in the full profile.

Beyond the preview

Go deeper on cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A (PDE10A).

Explore the full profile